Laura Bozal-Basterra

Laura Bozal-Basterra

Auto-generated profile, based on publicly available information

Laura Bozal-Basterra

Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
VTVeronica Torrano
Veronica Torrano
LVLorea Valcarcel-Jimenez
Lorea Valcarcel-Jimenez
ACAna Rosa Cortazar
Ana Rosa Cortazar
XLXiaojing Liu
Xiaojing Liu
JUJelena Urosevic
Jelena Urosevic
ACArkaitz Carracedo
Arkaitz Carracedo
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.

1 October 2017 in Neurobiology of Disease
Verified
Journal Article
Closed access
WSWandert Schaafsma
Wandert Schaafsma
LBLaura Bozal Basterra
Laura Bozal Basterra
SJSabrina Jacobs
Sabrina Jacobs
NBNieske Brouwer
Nieske Brouwer
PMPeter Meerlo
Peter Meerlo
BEBart J.L. Eggen
Bart J.L. Eggen

5 July 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MPMikel Pujana-Vaquerizo
Mikel Pujana-Vaquerizo
LBLaura Bozal-Basterra
Laura Bozal-Basterra
ACArkaitz Carracedo
Arkaitz Carracedo
Prostate cancer is one of the most commonly diagnosed cancers in men and is a major cause of cancer-related deaths worldwide. Among the molecular processes that contribute to this disease, the weight of metabolism has been placed under the limelight in recent years. Tumours exhibit metabolic adaptations to comply with their biosynthetic needs. However, metabolites also play an important role in supporting cell survival in challenging environments or remodelling the tumour microenvironment, thus being recognized as a hallmark in cancer. Prostate cancer is uniquely driven by androgen receptor signalling, and this knowledge has also influenced the paths of cancer metabolism research. This review provides a comprehensive perspective on the metabolic adaptations that support prostate cancer progression beyond androgen signalling, with a particular focus on tumour cell intrinsic and extrinsic pathways.

1 October 2019 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LALeire Arreal
Leire Arreal
MPMarco Piva
Marco Piva
SFSonia Fernández
Sonia Fernández
ARAjinkya Revandkar
Ajinkya Revandkar
ACAriane Schaub- Clerigué
Ariane Schaub- Clerigué
ACArkaitz Carracedo
Arkaitz Carracedo
Oncogene addiction postulates that the survival and growth of certain tumor cells is dependent upon the activity of one oncogene, despite their multiple genetic and epigenetic abnormalities. This phenomenon provides a foundation for molecular targeted therapy and a rationale for oncogene-based stratification. We have previously reported that the Promyelocytic Leukemia protein (PML) is upregulated in triple negative breast cancer (TNBC) and it regulates cancer-initiating cell function, thus suggesting that this protein can be therapeutically targeted in combination with PML-based stratification. However, the effects of PML perturbation on the bulk of tumor cells remained poorly understood. Here we demonstrate that TNBC cells are addicted to the expression of this nuclear protein. PML inhibition led to a remarkable growth arrest combined with features of senescence in vitro and in vivo. Mechanistically, the growth arrest and senescence were associated to a decrease in MYC and PIM1 kinase levels, with the subsequent accumulation of CDKN1B (p27), a trigger of senescence. In line with this notion, we found that PML is associated to the promoter regions of MYC and PIM1, consistent with their direct correlation in breast cancer specimens. Altogether, our results provide a feasible explanation for the functional similarities of MYC, PIM1, and PML in TNBC and encourage further study of PML targeting strategies for the treatment of this breast cancer subtype.

1 February 2018 in The American Journal of Human Genetics
Verified
Journal Article
Open access
LBLaura Bozal-Basterra
Laura Bozal-Basterra
IMItziar Martín-Ruíz
Itziar Martín-Ruíz
LPLucia Pirone
Lucia Pirone
YLYinwen Liang
Yinwen Liang
JSJón Otti Sigurðsson
Jón Otti Sigurðsson
RBRosa Barrio
Rosa Barrio
Townes-Brocks syndrome (TBS) is characterized by a spectrum of malformations in the digits, ears, and kidneys. These anomalies overlap those seen in a growing number of ciliopathies, which are genetic syndromes linked to defects in the formation or function of the primary cilia. TBS is caused by mutations in the gene encoding the transcriptional repressor SALL1 and is associated with the presence of a truncated protein that localizes to the cytoplasm. Here, we provide evidence that SALL1 mutations might cause TBS by means beyond its transcriptional capacity. By using proximity proteomics, we show that truncated SALL1 interacts with factors related to cilia function, including the negative regulators of ciliogenesis CCP110 and CEP97. This most likely contributes to more frequent cilia formation in TBS-derived fibroblasts, as well as in a CRISPR/Cas9-generated model cell line and in TBS-modeled mouse embryonic fibroblasts, than in wild-type controls. Furthermore, TBS-like cells show changes in cilia length and disassembly rates in combination with aberrant SHH signaling transduction. These findings support the hypothesis that aberrations in primary cilia and SHH signaling are contributing factors in TBS phenotypes, representing a paradigm shift in understanding TBS etiology. These results open possibilities for the treatment of TBS.

21 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSarah E. Conduit
Sarah E. Conduit
WPWayne Pearce
Wayne Pearce
ABAmandeep Bhamra
Amandeep Bhamra
BBBenoit Bilanges
Benoit Bilanges
LBLaura Bozal-Basterra
Laura Bozal-Basterra
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
Primary cilia are antenna-like organelles which sense extracellular cues and act as signalling hubs. Cilia dysfunction causes a heterogeneous group of disorders known as ciliopathy syndromes affecting most organs. Cilia disassembly, the process by which cells lose their cilium, is poorly understood but frequently observed in disease and upon cell transformation. Here, we uncover a role for the PI3Kα signalling enzyme in cilia disassembly. Genetic PI3Kα-hyperactivation, as observed in PIK3CA-related overgrowth spectrum (PROS) and cancer, induced a ciliopathy-like phenotype during mouse development. Mechanistically, PI3Kα and PI3Kβ produce the PIP3 lipid at the cilia transition zone upon disassembly stimulation. PI3Kα activation initiates cilia disassembly through a kinase signalling axis via the PDK1/PKCι kinases, the CEP170 centrosomal protein and the KIF2A microtubule-depolymerising kinesin. Our data suggest diseases caused by PI3Kα-activation may be considered ‘Disorders with Ciliary Contributions’, a recently-defined subset of ciliopathies in which some, but not all, of the clinical manifestations result from cilia dysfunction.